Dr. STEFANY CARDOSO FARIA - MÉDICO ONCOLOGISTA

Postagens

Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study

agosto 29, 2016

Lancet. http://ac.els-cdn.com/S014067361630592X/1-s2.0-S014067361630592X-main.pdf?_tid=2bbaab8c-6e22-11e6-91af-00000aacb361&acdnat=1472500552_267c801b1a8103d3afee87b33e288d1c 2016 Jul 26. pii: S0140-6736(16)30592-X. doi: 10.1016/S0140-6736(16)30592-X. [Epub ahead of print] Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study. Yaxley JW 1 , Coughlin GD 1 , Chambers SK 2 , Occhipinti S 3 , Samaratunga H 4 , Zajdlewicz L 5 , Dunglison N 1 , Carter R 6 , Williams S 7 , Payton DJ 8 , Perry-Keene J 8 , Lavin MF 9 , Gardiner RA 10 . Author information Abstract BACKGROUND: The absence of trial data comparing robot-assisted laparoscopic prostatectomy and open radical retropubic prostatectomy is a crucial knowledge gap in uro-oncology. We aimed to compare these two approaches in terms of functional and ...

Leia mais

Nivolumab Results in High Rate of Response in Refractory Classical Hodgkin's Lymphoma

agosto 29, 2016

· in this single-arm, phase II study, the authors evaluated the efficacy and safety of nivolumab monotherapy in 80 adults with recurrent classical Hodgkin's lymphoma following failure of autologous stem-cell transplantation and brentuximab vedotin. After a median of 8.9 months of follow-up, 66.3% of patients achieved an IRRC-assessed objective response. Common adverse effects included fatigue (25%), reaction to the infusion (20%), and rash (16%). The most common grade ≥3 adverse events were neutropenia (5%) and increased lipase concentrations (5%). There were 3 deaths during the study period but none was thought to be related to therapy. Treatment with nivolumab results in a response in the majority of patients with refractory Hodgkin's lymphoma, and the safety profile is acceptable. Nivolumab may represent a ...